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Abstract
T helper (Th2) cells are increased in asthma and mediate allergic inflammation through
production of type 2 cytokines (interleukin-4, -5 and -13). One pathway to activate Th2 cells
is through chemoattractant-homologous receptor expressed on Th2 cells (CRTh2), a receptor
for prostaglandin D2 (PGD2). Glucocorticoids (GCs) are the main treatment for allergic
disease, due to their ability to suppress type 2 cytokine production and induce apoptosis.
Incidence and severity of asthma is greater in women than men, which may be related to sexspecific efficacy of GCs. Recently, our laboratory found that severe asthmatic women had
more circulating Th2 cells than men and that the proportion of Th2 cells were positively
correlated with daily dose of inhaled GC in women, but not men. Since estrogen has been
shown to influence type 2 cytokine production, I hypothesized this pathway interferes with the
anti-inflammatory effect of GC on Th2 cells. I found that Th2 cells co-treated with an estrogen
receptor (ER) agonist and GC exhibited a significant increase in surface and total CRTh2
protein levels which was associated with enhanced IL-5 and IL-13 production in response to
PGD2. Th2 cell apoptosis induced by GC was reduced with ER agonism. These results show
that GC and ER signaling enhances Th2 cell responses and survival. In vivo this interaction
may represent a mechanism by which Th2 cells and type 2 responses are sustained in women,
influencing severity of asthma.
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Chapter 1

1

Introduction

The incidence and severity of asthma is greater in women than men; this may be related to sexspecific efficacy of GCs. Increasing evidence from clinical and animal model studies suggest
sex hormones, estrogen in particular, may play a role in the increased prevalence and severity
of asthma in women. Our recent study revealed that in severe asthmatics taking high dose GCs
there were significantly more circulating Th2 cells in women than men. Since estrogen has
been shown to induce the Th2 cytokine IL-13 in a mouse model of asthma and to be associated
with increased IL-5 in human sputum samples, it may play a role in influencing Th2 response
to GC. The aim of this study was to assess the interaction between estrogen and GC signaling
and determine the effect on Th2 cell function.

1.1

Asthma

Asthma is a chronic inflammatory disease that affects approximately 300 million people world
wide [1]. Among the various types of asthma, allergic asthma is the most common asthma
phenotype. Several cells of the innate and adaptive immune system work to bring about the
inflammatory processes that mediate asthma chronicity. These include immune responses,
bronchial hyper-reactivity, mucus secretion and remodeling of airways [2], features that
collectively give rise to the typical symptoms of asthma - coughing, wheezing and shortness
of breath.

1.1.1

Asthma Diagnosis

Asthma is currently diagnosed based on clinical presentation as well as objective lung function
measures. Forced expiratory volume in 1 second (FEV1) is determined using a spirometer and
measures the maximum volume delivered during expiration in one second [3]. Asthma is
defined by reversible airway obstruction, determined by improvement of FEV1 at least 12%
and 200 mL of lung volume following administration of a bronchodilator [3]. An alternative
assessment of lung function is the methacholine challenge test, which is recommended for
patients that present with characteristics of asthma but display normal spirometry results. In
1

the methacholine challenge test patients are given increasing doses of methacholine, which
induces bronchoconstriction. In this diagnostic test positive results are identified by a 20%
reduction in FEV1 [4] and hypersensitivity occurring with less than 8 mg/mL of methacholine.
More targeted approaches can be used, such as sputum eosinophilia, to identify specific asthma
phenotypes [5]. As new treatment strategies become available, there is a need for improved
diagnosis of the various asthma phenotypes.

1.1.2

Asthma Treatment

Patients with allergic asthma are managed with a combination of medications such as inhaled
corticosteroids, which reduce asthma associated inflammation and with a short or long acting
2-adrenergic agonist which provides relaxation when there is bronchoconstriction of the
airways [6]. These medications generally come in the inhaler form to allow for direct entry
into the airways and improve asthma symptoms and airway function [6]. Some examples of
inhaled corticosteroids include budesonide, ciclesonide, fluoconolide, fluticasone and
beclomethasone [7]. Patients can also be given oral or intravenous medications to provide
systemic relief of symptoms.

1.1.3

Categories of Asthma

Allergic vs non-allergic asthma
Although the clinical manifestation of asthma can range from mild to severe, the mechanism(s)
underlying the pathogenesis of these two types of asthma are largely mediated by inflammatory
cells and their mediators. All asthma is characterized by inflammation of the airways. Allergic
inflammation is mediated by an increase in the proportion of circulating eosinophils, mast cells,
macrophages and T lymphocytes (T cells) and type 2 responses within the blood and airways
[8]. Non-allergic asthma is found in individuals within whom allergic sensitization cannot be
demonstrated. This form of asthma is characterized by airway neutrophils as well as a Th1polarized response reflected by increased interferon gamma (IFN-γ), lymphototoxin and IL-2
levels in response to foreign pathogens such as viruses and mycobacteria [9].

2

Asthma severity
The Global Initiative for Asthma (GINA) categorizes asthma into intermittent, mild, moderate
or severe based on clinical features, medications prescribed as well as individual response to
treatment [10]. Severe asthma is defined as asthma which requires management with a high
dose of inhaled corticosteroid along with a second controller to prevent symptoms from
becoming worse or asthma which remains poorly controlled despite this type of therapy [11].
Although severe asthmatics comprise 5-10% of individuals with asthma, this population
experiences more exacerbations requiring hospitalizations and also experiences poor response
to treatment [12]. While glucocorticoids (GCs) are used to inhibit inflammatory molecules,
severe asthmatics experience a persistence of symptoms and lack of asthma control despite
receiving a high-dose of inhaled corticosteroid and an additional controller or even oral
corticosteroid treatment [12]. This presents a major barrier to effectively managing severe
asthma.

1.2

Development of Asthma

The immune system works to defend the body against invading foreign entities using both
innate and adaptive immunity. The innate immune system provides a first line of defense
facilitated by ancient receptors that recognize molecular patterns within microbes and allow
for rapid responses. The airway epithelium plays an important role in innate immunity as it
serves both as an interface between the external environment and cellular activities within the
lung, such as microbial activation of macrophages and neutrophils. The adaptive immune
system requires more time to develop, since it mediates highly specific responses directed
against antigens and primarily involves T and B lymphocytes [13]. Dendritic cells are also
present within the mucosal lining of airway epithelium and are important immune cells as they
function both as innate cells, detecting foreign antigens, as well as ‘bridging cells’ that interact
with T lymphocytes and initiate development of adaptive immune response [14].

1.2.1

Antigen Presentation

Antigen presenting cells (APC) are a diverse group of immune cells that primarily mediate the
adaptive immune response by recognizing, processing and presenting an antigen to T
3

lymphocytes. Many cell types can present antigens, including dendritic cells, macrophages,
langerhans cells and B cells. Of these, dendritic cells are most prominent in the lung epithelia
and play a key role in the stimulation of naïve T cells [14]. Upon antigen uptake, dendritic cells
migrate to local lymph nodes and undergo a process of maturation into highly efficient cells
that present antigenic peptides to naïve T cells [15]. Mature dendritic cells process antigen into
peptides which are presented to CD4+ T helper (Th) cells in major histocompatibility
complexes (MHC) class II molecules in the draining lymph node [15]. Mature dendritic cells
express cell surface co-stimulatory molecules that synergize with antigen during naïve T cell
activation. CD28 is a co-stimulatory receptor present on naïve T cells which binds CD80 and
CD86 ligands that are upregulated when dendritic cells are stimulated [16]. Simultaneous
presentation of antigen via MHC class II molecules and co-stimulatory signals promote naïve
T cell clonal expansion and differentiation into an effector T cell fate.

1.2.2

Adaptive Immune Response

The adaptive immune response requires time to develop because it involves clonal expansion
of B and T lymphocytes. These cells are activated by triggering of their receptors that recognize
peptides of foreign antigens. These antigen-specific cells allow the immune system to
“remember” the antigen and provide a more rapid response to subsequent exposures [13]. In
the case of a pathogen, this recognition is beneficial as it provides rapid responses with
protection immunity. However, the immune system can also develop memory to seemingly
innocuous substances, such as house dust mites or tree pollen. In this case, the ability to rapidly
respond can be problematic as it triggers allergic responses and if exposure is ongoing can
facilitate chronic inflammation.

1.2.3

CD4+ T Lymphocyte Subsets

A number of T cell subsets existing within the immune system mediate the adaptive immune
response. Currently, naïve CD4+ Th cells have been shown to differentiate into a number of
lineages some of which include follicular helper T (Tfh), Th1, Th2, Th17 and T regulatory
cells (Tregs). The differentiation into one of these lineages is determined by the activation of
transcription factors and secretion of cytokines; Tfh by Bcl6, Th1 by IL-12 and IFN-γ, Th2 by
4

IL-4, and Treg by IL-2 and transforming growth factor beta (TGF-) [17] [18] (Fig. 1). Immune
and effector responses of T cells are influenced significantly by these various CD4+ T cell
subsets.

Figure 1: Naïve CD4+ Th cell Lineages. Naïve CD4+ Th cells can differentiate into lineages
including Tfh, Th1, Th2, Th17 and T regulatory cells (Tregs). The differentiation into one of
these five lineages is determined by the activation of transcription factors and secretion of
cytokines; Tfh by STAT-3 and Bcl6, Th1 by STAT4, T-bet and IL-12, Th2 by STAT-6,
GATA-3 and IL-4, and Treg by FOXP3 and TGF-. Abbreviations are as follows: Signal
Transducer and Activator of Transcription Factor, STAT; B cell Lymphoma, Bcl; Forkhead
Box P3, FOXP3; Transforming Growth Factor Beta, TGF-.
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1.2.4

The Th1 and Th2 cell Paradigm

During the 1980s, Mosmann et.al. discovered functionally distinct Th cell populations, termed
Th1 and Th2 cells based on the different cytokines released in response to antigen [19] and
later determined to be largely dependent on activation of different transcription factors [20].
Th1 responses are characterized by increased IL-2 and IFN- and play a role in viral and
bacterial infections [19]. On the other hand, Th2 cells produce IL-4 which promotes Th2 cell
differentiation and IgE production [19], IL-5 which mediates differentiation and survival of
eosinophils as well as IL-13 which also plays a role in production of IgE, mucous and airway
remodeling [20]. Furthermore, both Th subsets are mutually inhibitory. IFN- secreted by Th1
cells promotes Th1 but inhibits Th2 cell development, while Th2 cells secrete IL-4 which
inhibits Th1 cell differentiation [19, 21].

1.2.5

Development of Th2 cells

Differentiation of naïve CD4+ T cells can be initiated with antigen stimulation which occurs
when there is cross-linking between T cell receptor (TCR) and CD3 with antigens that are
presented on dendritic cells via MHC II complexes [22]. TCR and CD3 activation initiates
downstream signaling cascade leading to naïve T cell differentiation into different effector
cells [22]. Differentiation into specific effector cell fates is highly dependent on the cytokines
present, APCs, and costimulatory factors. Differentiation into the Th2 cell phenotype can be
initiated by the presence of IL-2 and IL-4 [18]. STAT6 is a transcription factor that is induced
by IL-4 and works to increase the expression GATA-3, a Th2 transcription factor. GATA-3
promotes Th2 cell differentiation by promoting type 2 cytokine secretion [18], Th2 cell
differentiation through growth factor independent-1(Gfi-1), a transcriptional repressor and by
the inhibition of Th1 cell proliferation which is initiated via T-bet [23, 24] or via STAT4
downregulation [18, 23-25] (Fig. 1).

1.2.6

Type 2 Inflammation

Type 2 inflammatory responses are mediated by both adaptive and innate immunity. Firstly,
differentiation of CD4+ T cells into type 2 helper T cells (Th2). Secondly, microbes deposited
onto epithelium that lead to secretion of IL-25, IL-33 and thymic stromal lymphopoietin
6

(TSLP) [26], mediators that promote the production of type 2 cytokines IL-5, IL-9, and IL-13
by innate immune cells such as type 2 innate lymphoid cells (ILC2), nuocytes and natural killer
cells [27]. TSLP promotes dendritic cell, mast cell, basophil, monocyte, and natural killer cell
activation and also plays a key role in the maintenance of Th2 cells [28, 29]. IL-25 has also
been shown to promote the differentiation of CD4+ T cells into the Th2 cell phenotype [28,
30]. Therefore, type 2 immune responses are orchestrated by both Th2 cells and ILC2 cells
[31].

1.2.7

Type 2 Cytokines

Cytokines are extracellular proteins released by cells and these proteins interact and effect the
behavior of other cells bearing their receptors [32]. Cytokines are key inflammatory mediators
as they play a crucial role in the persistence and maintenance of asthmatic symptoms and
inflammation associated with asthma. The type 2 inflammatory response is characterized by
the production of IL-4, IL-5 and IL-13. IL-4 is produced by naïve T cells, mast cells, basophils
and CD4+ Th2 cells [33]. It promotes initiation of Th2 cell differentiation and has also been
shown to play a role in airway remodeling through its ability to promote cells like fibroblast to
produce mucus [33]. IL-5 plays an important role in the regulation, activation and survival of
eosinophils [34]. Eosinophilia has been reported in the blood, spleen and bone marrow of mice
constitutively expressing IL-5. Failure to stimulate eosinophil production and hyper-reactivity
was also found in IL-5 deficient mice, further implicating a role for IL-5 in allergic asthma
[35]. IL-13 binds to the IL-4 alpha receptor (IL-4R) and also plays a number of roles in
inflammation such as inducing goblet cell hyperplasia, mucus production and has been found
to be highly expressed in the airways of asthmatics [36]. Both IL-4 and IL-13 stimulate B cell
isotype switching to produce Immunoglobulin E (IgE) antibodies [33]. Secreted IgE antibodies
bind to high affinity IgE receptor (FcεRI) on mast cells [33]. Upon exposure to an allergen,
receptor bound IgE on these effector cells degranulate and release potent chemical mediators
(eg. Histamine, PGD2) stored within their granules, leading to allergic symptoms [37]. Thus,
these inflammatory changes that take place within the airway mucosa facilitate the
development of heighten responses to inhaled allergens. Type 2 cytokines also initiate other
aspects of asthma, such as remodeling of the airway, activation of endothelial cells and
7

recruitment of effector cells such as mast cells, basophils and eosinophils [38]. Newly
developed treatments targeting IL-4, -5 and -13 show that suppression of these inflammatory
mediators improves asthma symptoms and further highlights their role in the pathobiology of
asthma [39].

1.3

CRTh2-PGD2 Pathway

Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) is a Gprotein coupled receptor for the lipid mediator prostaglandin D2 (PGD2) [40] and is implicated
in allergic inflammation. Firstly, when expressed by CD4+ T cells, it serves as a marker of the
Th2 cell subset, however, it is also expressed by ILC2s [41] and eosinophils [42]. PGD2 is a
lipid mediator derived from arachidonic acid metabolism via cyclooxygenase and
prostaglandin synthase which allows for the production of prostaglandins [43]. PGH2 is
catalyzed to PGD2 via the enzyme PGD synthase, which is then subsequently released from
mast cells following allergen activation [44]. With a half-life of approximately 30 minutes,
PGD2 is metabolized very quickly [45]. The effects of PGD2 are mediated via binding to Gprotein coupled receptors which include CRTh2 (D prostanoid receptor 2), DP1 and
thromboxane prostanoid receptor. PGD2 binding to DP1 receptor facilitates the inhibition of
Th1 responses as well as increases relaxation of smooth muscles, vasodilation, and
permeability of vascular membranes ultimately leading to the migration of leukocytes to
inflammatory sites [46]. Activation of CRTh2 by PGD2 mediates type 2 inflammatory
responses through induction of IL-4, -5, and -13 production [41]. CRTh2 activation also
induces Th2 cell and ILC2 chemotaxis in vitro as well as recruitment of eosinophils and
basophils to tissues in vivo [40]. Aside from a role in inflammatory processes, CRTh2 has been
shown to play a part in normal physiological processes as well. For instance, during pregnancy
the immune system favors a bias towards Th2 type responses to allow for maternal tolerance
and protection of the fetus [47]. PGD2 production by the placenta during pregnancy can play a
role in promoting Th2 bias through CRTh2 [48]. The PGD2-CRTh2 pathway has also been
shown to play a protective role in skin homeostasis [49]. CRTh2 activation by PGD2 results in
the production of beta-defensin-3 an antimicrobial peptide that protects skin from infection
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[49]. Therefore, although the PGD2-CRTh2 pathway can promote inflammatory responses, it
has also been shown to have protective effects.

1.3.1

Role of CRTh2-PGD2 Pathway in Allergic Asthma

Studies have shown a role for the CRTh2-PGD2 pathway in allergic lung inflammation. Indeed,
CRTh2 deficient mice displayed protection from bronchial hyper-responsiveness as well as
mucus production [50]. In other mouse model studies, administering CRTh2 antagonists
reduced airway hyperreactivity via reduction of IgE, IgG1 and IgG2a as well as through a
reduction of mucus secretion and leukocyte infiltration into the airways [51]. Furthermore,
single nucleotide polymorphism (SNP)s in CRTh2 have also been associated with several
allergic phenotypes [8]. For instance, the AA genotype of the CRTh2 rs533116 SNP has been
associated with the development of allergic asthma [8, 52]. Individuals carrying this SNP had
increased CRTh2 expression, percentage of circulating eosinophils, and demonstrated a 2-fold
increase in cells expressing IL-4 and IL-13 compared to cells of the GG phenotype [8]. Higher
levels of both PGD2 and the proportion of total cells expressing CRTh2 have been found in the
bronchoalveolar lavage (BAL) fluid obtained from severe asthmatics taking a high dose of
inhaled corticosteroid, compared to those with non-severe asthma [53]. CRTh2+ cells and
PGD2 were also correlated with worse asthma control and more asthma exacerbations [53].
Similarly, our laboratory recently reported results showing that severe asthmatics also had a
higher proportion of circulating Th2 cells (CD4+CRTh2+ T cells) than those with
mild/moderate disease and that serum PGD2 levels were elevated in those that had exacerbated
in the last year [54]. These data suggested that tracking the combined metric of % Th2 cells
and serum PGD2 levels may help identify severe asthmatics at risk of exacerbation [54].

1.4

Glucocorticosteroids

Glucocorticoids (GCs) are a form of steroid hormone with the ability to modulate a number of
biological functions. GCs are widely used to suppress pro-inflammatory responses and they
also display strong immunomodulatory effects. These include their ability to reduce type 2
cytokines and chemokines and to promote T cell apoptosis [55], thereby reducing the presence
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of airway inflammatory cells such as eosinophils, T cells and mast cells. As such, they are one
of the most effective controllers for asthma [55].

1.4.1

Glucocorticoids Mechanism of Action

The potent anti-inflammatory effects exhibited by GCs are mediated via the glucocorticoid
receptor (GR), a part of the nuclear receptor superfamily known to have diverse domains that
assist transactivation, dimerization, binding of DNA segments and nuclear localization [56].
The GR has two major isoforms; GR alpha (GR) and GR beta (GR). GR is widely
expressed throughout the body and primarily plays a role in the induction or repression of
various gene targets [56]. Contrarily, GR has been shown to act as a dominant negative
inhibitor of GR activity by affecting transactivation and transrepression through the
formation of GR/ heterodimers [56]. The classical GC signaling mechanisms include
transactivation and trans-repression. Transactivation is when GC binds to cytoplasmic GR,
forming a complex that undergoes a conformational change and translocates to the nucleus.
These complexes homodimerize, bind to GC response elements (GRE) within promoters of
genes such as FK506 binding protein 5 (FKBP5), glucocorticoid-induced leucine zipper
(GILZ), and dual specificity phosphatase (DUSP), inducing their expression [57] (Fig. 2).
Complex binding sites can also have co-activator or co-repression molecules that either inhibit
or allow for the transcription of anti-inflammatory cytokines [57]. Gene expression can also
be repressed when the GC-GR complex binds to negative GREs, this has commonly been
found to be associated with side effects which can include inhibition of osteocalcin, a protein
required for bone synthesis which is commonly seen in patients using GCs [58] (Fig. 2).
Transrepression is when GC-GR interact with other transcription factors like nuclear factorB (NFB) and activator protein-1(AP-1) [57, 59]. GR can bind these transcription factors and
inhibit their ability to induce transcription of pro-inflammatory cytokines, this mechanism has
also been shown to influence GC resistance in some patients [60] (Fig. 2). Furthermore,
inhibition of transcription factors such as NFB have been shown to be essential in mediating
GC repression of inflammatory cytokines such as tumor necrosis factor alpha (TNF-) and IL1 [61]. The time frame of GC effects vary as GC responsive genes have been shown to be
regulated between 40-53 minutes after GC treatment [62]. Aside from these signaling
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mechanisms, GCs have also been shown to effect mRNA stability [63]. Indeed, a study found
that GCs reduced the mRNA stability of growth factors required for keratinocytes [63].
Therefore, it is also possible for GCs to indirectly modulate gene expression by affecting
mRNA turnover.

Figure 2: Glucocorticoid Regulation of Gene Expression. Glucocorticoids regulate gene
expression in several ways. 1. Transactivation Transcription can occur via transactivation
where GC binds to cytoplasmic GR translocating to the nucleus, homo-dimerizing and binding
to positive GREs within the promoter of targeted genes. 2. Transrepression Gene expression
can be regulated when GC-GR interact with transcription factors like NFB, inhibiting the
transcription of pro-inflammatory cytokines such as IL-5, IL-13, TNF- and IL-1 [61]. 3. Gene
expression can also be influenced by transactivation when the GC-GR complex binds to
negative GREs, inhibiting transcription [57].
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1.4.2

Apoptosis

Apoptosis is a regulated, non-inflammatory method of cell death that plays an important role
in cell homeostasis and resolution of inflammation. Apoptosis is mediated by an intracellular
proteolytic cascade that involves the removal of the mitochondria, loss of plasma membrane
integrity and formation of apoptotic bodies [64]. These processes are largely mediated by a
family of caspases which belong to aspartate specific proteases [65]. The process of apoptosis
is essential for immune regulation and can occur during thymocyte development due to
excessively weak or strong affinity for MHC or self-peptides [66].

1.4.3

Intrinsic and Extrinsic Apoptosis

Apoptosis can be induced in cells via two distinct pathways. During negative selection of
lymphocytes that have become autoreactive or during cellular stress the intrinsic apoptotic
pathway can be initiated [67]. The intrinsic apoptosis pathway is regulated by the B-cell
lymphoma 2 (BCL-2) family of intracellular proteins [68], and it involves disruption of the
outer mitochondrial membrane [69]. This results in release of apoptotic mediators such as
cytochrome C [69]. The apoptosis pathway is mediated via the balance of pro- and antiapoptotic members of the BCL-2 family. Pro-apoptotic members of this family include BCL2-like protein 11 (BIM), BCL-2 associated death promoter (BAD), p53 upregulated modulator
of apoptosis (Puma), BH3 interacting-domain death agonist (Bid) and NADPH oxidase
activator (Noxa) are pro-apoptotic [68]. BCL-2 associated X protein (Bax) and BCL-2
homologous antagonist killer (Bak) become activated once Puma and Noxa receive apoptotic
stimuli which can include various insults to the cell such as DNA damage or membrane
disruption. Anti-apoptotic members of this family like BCL-2 and B-cell lymphoma-extra
large (BCL-xL) can counteract the process by neutralizing pro-apoptotic members (Bak or
Bax) [70] by keeping them as monomers, preventing their oligomerization and pore creation
[70]. Other members like BIM or BAD promote apoptosis by displacing BCL-2 or BCL-xL,
allowing for pore formation in the mitochondrial membrane by Bak or Bax [70]. Pore
formation results in the release of cytochrome C following the formation of the apoptosome
which contains Apaf1 and caspase-9 that activate caspase-3 and mediate the final events of
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apoptosis [70]. Therefore, balance between pro and anti-apoptotic members of the BCL-2
family is essential in determining cell survival.
The extrinsic apoptosis pathway is initiated via the activation of cell death receptors such as
Fas which precedes ligation and oligomerization ultimately resulting in the activation of
caspase-8 and then caspase-3 [71]. Activation of caspases results in the cleavage of the proapoptotic molecule Bid allowing for mitochondrial membrane destabilization [69]. Despite the
various initiators of either the intrinsic or extrinsic apoptotic pathway, both pathways result in
the activation of caspase-3, an irreversible process which ultimately leads to cell death.

1.4.4

Glucocorticoids and Apoptosis

Studies strongly implicate a role for members of the BCL-2 family to be involved in GC
mediated apoptosis. For instance several studies suggests that GCs primarily use the intrinsic
apoptosis pathway and mediate apoptosis by reducing anti-apoptotic proteins like BCL-2 and
BCL-xL thereby allowing for caspase-3 activation [72]. Transgenic mice overexpressing BCL2 block glucocorticoid induced apoptosis [73, 74]. Furthermore, over expression of BCL-2 in
murine T hybridoma cell lines resulted in the inhibition of cytochrome C as well as apoptosis
inducing factor (AIF) release following GC treatment [75]. BCL-2 is commonly found in the
mitochondria and endoplasmic reticulum also suggesting these organelles have a function in
GC induced apoptosis [76]. BIM is another member of the BCL-2 family found to be
implicated in GC induced apoptosis. BIM is upregulated upon GC treatment in T cell
lymphoma cell lines and GR has been found to bind to BIM regulatory elements [77, 78].
Furthermore, transgenic mice deficient in BIM showed a significant impairment of GC induced
apoptosis suggesting this BCL-2 family member plays a crucial role in GC induce apoptosis
[73, 74].

1.4.5

Glucocorticoid Resistance and Severe Asthma

In most patients, inhaled GCs effectively reduce inflammatory cells and improve asthma
symptoms [79]. However in severe asthma, which comprises 5-10% of individuals with
asthma, patients take high dose inhaled GCs and bronchodilators but still have persistent
symptoms and poor lung function [79]. Indeed, some individuals with severe asthma are likely
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steroid-resistant, as studies have also shown a subset of patients that respond poorly even after
a week of oral steroid treatment [80], while others may simply need higher doses of inhaled
GC to achieve anti-inflammatory responses. Several mechanisms have been suggested to be at
play which all seem to interfere with GC metabolism, GR activation, nuclear translocation
and/or DNA binding [81].

1.5

Asthma in Women

Understanding whether sex plays a role in certain health conditions is important, since
symptoms and response to treatment may differ significantly between men and women [82].
Indeed, sex differences are seen in various diseases such as autoimmune diseases like multiple
sclerosis and lupus, as well as in cardiovascular diseases and osteoporosis [83]. Sex differences
are also seen in diseases like asthma where boys tend to outgrow their asthma, while it
increases with age in girls [84]. In adults, asthma is more prevalent in women and they are
twice as likely as men to have severe asthma [85]. Additional to the large burden that asthma
places on human health, it also remains to be one of the most common reasons for hospital
admissions in Canada. Indeed, women are more likely than men to have an asthma
exacerbation needing hospitalization [86, 87] and it has been reported that women have an
increased rate of hospitalization due to asthma related symptoms [88]. Although considerable
research has improved our understanding of this disease, underlying mechanism(s) for the sex
difference in asthma prevalence are not known.

1.5.1

Glucocorticoid Resistance in Women

Though there is much data to suggest there are differences in men and women with severe
asthma, few studies have examined the underlying mechanism. One possibility is differences
in GC efficacy as one study showed that the inhaled corticosteroid fluticasone propionate
improved airway responsiveness in men better than women [89]. Interestingly, our laboratory
has recently found that the level of circulating Th2 cells in severe asthmatics was significantly
higher in women than men (App. 1.1) and that there is a positive correlation between the
proportion of circulating Th2 cells and total daily dose of inhaled corticosteroids (ICS) in
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women, but not men (App. 1.2). Our observations suggest that responses to GC may differ
between men and women.

1.5.2

Sex Hormones and Asthma

During childhood the prevalence of asthma is higher in boys than girls, however, with the onset
of puberty, the trend shifts and by adulthood, women have more asthma the men [90]. Other
physical changes such as menstruation, pregnancy and menopause have been associated with
increased asthma symptoms and/or incidence, suggesting that mediators such as sex hormones
may play a role in asthma and allergic inflammation [91]. During the reproductive years,
females experience cyclical fluctuations in sex hormones. Estradiol (E2; 17-β-Estradiol) is the
primary form of estrogen produced during this period of life. The menstrual cycle is primarily
divided in two major phases - the luteal phase and follicular phase [92]. The menstrual cycle
runs for a duration of approximately 28 days and is classified by cyclical variations in the sex
hormones estrogen and progesterone [92]. The follicular phase accompanies gradual rising of
estrogen levels that peak during the beginning of the luteal phase where there is gradual
decrease in estrogen and rising progesterone levels [92]. Approximately one third of patients
experience exacerbation of asthma symptoms during the luteal phase of the menstrual cycle
[93]. The mechanisms underlying exacerbations may be related to high estrogen
concentrations, commonly seen during the luteal phase of the menstruation cycle [93] (Fig. 3).
Perimenopause is characterized by a period in which endogenous E2 levels are high, relative
to progesterone. Menopause is a predictor of late onset asthma [91], increasing risk by > 3-fold
[94]. This could be related to the spike in estrogen levels during peri-menopause (mid-40-50s)
[95, 96] or hormone replacement therapy (HRT) [97]. In post-menopause, estrogen levels are
low but stable throughout the month and may still play a role in health as elevated E2 levels
have been associated with development of cardiovascular disease [98] and breast cancer [99].
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Figure 3: Menstrual Cycle Hormone Levels. This graph indicates how normal hormones
fluctuate during the follicular and luteal phase of the menstrual cycle. Estrogen and
progesterone concentrations remain the lowest during the beginning of the follicular phase
which lasts approximately 14 days. With ovulation the luteal phase begins which is
characterized by a surge in estrogen and progesterone levels.
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1.5.3

Estrogen and Estrogen Receptors

Estrogen is a steroid sex hormone that plays a role in a wide range of tissues within the body.
E2 is the predominant form of estrogen in the human body, however, other forms of estrogens
exist, such as estrone and estriol [100]. Biological effects of estrogen are mediated via its
binding to either of its two nuclear receptors, estrogen receptor (ER) alpha (α) or beta (β) which
can be found throughout the body [101]. These receptors are coded by the ESR1 (ERα) and
ESR2 (ERβ) genes, located on different chromosomes [101]. Both receptors have various
mRNA splice variants that are highly expressed in diseased and normal tissue [102]. Higher
expression of ERα over ERβ has been implicated in the progression of various diseases such
as asthma, breast cancer, osteoporosis and cardiovascular diseases [102]. G-protein coupled
estrogen receptor (GPER) is another recently discovered estrogen receptor which has been
found to be located on the cell membrane [103].

1.5.4

Estrogen Signaling Mechanism

Estrogen receptors exert their effects through the regulation of transcriptional processes. ERα
and ERβ are bound to heat shock proteins in the cytoplasm. Classical estrogen receptor
signaling includes estrogen, binding to its receptor in the cytoplasm, translocating to the
nucleus, binding as a homodimer to the promoter of genes containing estrogen response
elements (EREs) and mediating gene transcription [101] (Fig. 4). The ligand binding domain
also undergoes a conformational change upon binding estrogen hormone further allowing for
the recruitment of key co-activator proteins. Studies show that gene expression can also be
indirectly modulated via estrogen receptors [101]. This indirect mechanism occurs via proteinprotein interactions with DNA-binding transcription factors within the nucleus or proteins such
as activator protein 1 (AP1) or SP1 located in the promoters of genes that are responsive to
estrogen [101]. Interactions with these proteins allow for the recruitment to the promoter of
co-activator or corepressor proteins allowing for changes in mRNA and protein production
(Fig. 4). Non-genomic estrogen signaling can also occur through membrane estrogen receptors
(GPER), which mediates effects through activation of protein kinases [101].
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Figure 4: Estrogen Regulation of Gene Expression. Estrogen regulated transcriptional
processes occur by three mechanisms. 1. The classical signaling mechanism involves estrogen
diffusing through the cell and binding to its receptor which is located in the nucleus. Upon
binding receptors dimerize and bind to the promoter of genes containing EREs allowing for
transcription of the gene of interest. 2. In the ERE independent mechanism there is proteinprotein interactions with DNA-binding transcription factors within the nucleus or on proteins
located in the promoter of genes that are responsive to estrogen which either work to allow or
inhibit transcription. 3. In the non-genomic signaling pathway estrogen can mediate its effects
by membrane ERs or non-ER plasma membrane associated estrogen-binding proteins which
can allow for the modified function of proteins within the cytoplasm as well as gene expression
changes. This non-genomic pathway is typically mediated via the activation of protein kinase
cascades.
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1.5.5

Estrogen and Th2 Inflammation

Allergic asthma is mediated by type 2 inflammation. Interestingly, elevated estrogen levels
have been associated with sputum IL-5 concentration during the luteal phase of the menstrual
cycle [93]. Another study compared immune responses during luteal and follicular phase and
found that the peripheral immune response is shifted to favor a Th2 response indicated by high
IL-4 producing Th cells during the luteal phase [104]. Since the luteal phase is characterized
by increases in estrogen this may suggest a role for estrogen in mediating Th2 responses.
Pregnancy is classified by increased estrogen and progesterone levels, this physiological state
has been shown to promote a type 2 cytokine milieu as IL-4 and IL-10 levels were found to be
significantly elevated during the first weeks of pregnancy [105]. Therefore, it may also be
possible that sex hormone fluctuations of estrogen commonly seen during pregnancy also
promote Th2 responses during pregnancy.

1.5.6

Estrogen and Th2 cell Survival

Studies suggest that hormones effect T helper cell survival via their impact on specific antiapoptotic molecules, namely BCL-2/BCL-xL [106]. These anti-apoptotic proteins are also
involved in estrogen mediated inhibition of apoptosis as estrogen signaling has been shown to
significantly increase BCL-2 expression which allows for the selective survival of particular T
cell subtypes [106]. Furthermore, treatment with varying concentrations of estradiol showed a
decrease in apoptosis of peripheral blood lymphocytes, which was related to induction of BCL2 [107]. Huber et. al. reported a similar result in which Th2 cells treated with E2 showed
increased BCL-2 expression [106]. Collectively, these studies suggest that Th2 cells may
preferentially survive in the female environment resulting in a dominance of humoral immune
responses through a BCL-2 mediated mechanism.

1.5.7

ER and Asthma

Several immune cells including CD4+ T cells have been shown to express both ERα and ERβ
[101]. This coincides with findings that suggest estrogen signaling is relevant to the
pathogenesis of allergic inflammation in the lung during asthma. Interestingly, mounting
evidence from the studies suggest a role for ER particularly over ERβ to promote Th2
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inflammatory responses and asthma. For example, administering estrogen at high
concentrations in ovariectomized mice increased IL-4 and GATA3, a Th2 transcription factor,
in a dose dependent manner and the effect was lost in ER deficient mice [108]. Estrogen has
also been shown to stimulate type 2 cytokine production through ER since in a mouse model
of allergic inflammation, female mice treated with ER antagonists displayed a reduction in
the production of type 2 cytokines IL-5 and IL-13 [109]. In contrast, when treating cells from
allergic mice with E2 in vitro an induction of IL-5 and IL-13 was seen [93].

1.5.8

Estrogen and GC Interactions

A role for estrogen interfering with GC in autoimmune inflammatory diseases has been
suggested, as women exhibit increased disease severity as well as reduced responsiveness to
corticosteroid treatment [110]. This may be due to cross-talk between sex hormone receptors
such estrogen and GCs. While there is little evidence to support cross-talk in cell types like
Th2 cells, studies have shown these interactions in breast cancer cell lines [111]. One study
showed that ERα and GR can work together in breast cancer to compete for co-factors involved
cancer cell proliferation [112, 113]. This study conducted a chromatin immunoprecipitation
(ChIP) analysis for GR in MCF-7 cells and showed that GR binds multiple ERE sites in the
presence of estrogen and GC [113] and was due to direct protein-protein interaction between
DNA binding domains of ERα and GR [113]. ERα and GR have also been shown to work
against one another as GR has been shown to play a role in the trans-repression of genes that
are regulated by ER in breast cancer thereby resulting in inhibition of cell proliferation [114].
Another study demonstrated that estrogen does not directly affect GR nuclear translocation but
indirectly impacted GR activity by decreasing GR phosphorylation through upregulation of
protein phosphatase 5 (PP5) [115]. PP5 depletion influenced increased GC induced reduction
of cell proliferation in the presence of estrogen [115], suggesting effects may be indirect.
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1.6

Rationale

Although considerable research has improved our understanding of the pathogenesis of
asthma, the role of sex in asthma prevalence and severity is not well understood. Currently, the
predominant treatment for asthma is inhaled GCs, which assist in suppressing proinflammatory responses [59]. Women, however, are found to be more susceptible to develop
corticosteroid-resistant or “hard to treat” asthma than men [108], which may be due to
differences in GC efficacy between men and women [89]. Our laboratory found that severe
asthmatic women have more circulating Th2 cells than severe asthmatic men (App. 1.1) and
that the level of Th2 was positively correlated with total daily dose of inhaled GC in women,
not men (App. 1.2). Since, studies have shown cross-talk between ERα and GC receptors [111],
my project examined whether estrogen signalling influences Th2 cell responses to GC.

1.7
1.7.1

Hypothesis & Objectives
Hypothesis

Th2 cell responses to glucocorticoids are influenced by estrogen receptor signaling leading to
enhanced Th2 cell function and survival.
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1.7.2

Objectives

Objective 1: To determine the effects of estrogen signaling on pro-inflammatory capacity
of Th2 cells
The Th2 subset is identified by expression of CRTh2 by CD4+T cells [41]. The ligand for
CRTh2 is the lipid mediator PGD2, which is released from mast cells following allergen
activation [41]. Activation of CRTh2 by PGD2 mediates chemotaxis, reduces apoptosis and
leads to type 2 cytokine production [41, 116]. GC are the most common treatment for allergic
asthma because they suppress inflammatory gene expression, particularly type 2 cytokines
[59]. While reports suggest that GR and ER may interact, this has not been examined in Th2
cells or in the context of type 2 cytokine expression. Here, I investigated the influence of ERα
signaling on Th2 cell response to GC.
Hypothesis: Activation of GC and ER induces CRTh2 levels and enhances production of
type 2 cytokines in response to PGD2

Objective 2: To identify whether estrogen receptor signaling inhibits GC induced
apoptosis of Th2 cells
Our lab has shown that GC treatment induces apoptosis in Th2 cells [117] and that severe
asthmatic women had more circulating Th2 cells than men (App. 1.1). This may be due to
estrogen mediating Th2 cell survival in women, leading to the accumulation of Th2 cells. It
has been shown that exposure of Th2 cells to E2 enhanced the expression of anti-apoptotic
proteins such as BCL-2 and BCL-xL [106]. Therefore, I studied the influence of ER signaling
on GC induced apoptosis. type 2 cytokine expression.
Hypothesis: GC-induced apoptosis of Th2 cells is inhibited by ER activation
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Chapter 2

2

Materials and Methods

2.1

Cell Culture

2.1.1

CCRF CEM Cells

CCRF CEM cells, an immortalized lymphocytic CD4+ T cell line, was purchased from
American Type Culture Collection (VA, USA) and grown in RPMI-1640 media (Sigma
Aldrich, ON, Canada) supplemented with 10% Fetal Bovine Serum (FBS) (Hyclone Scientific,
Fisher Scientific, Ontario, Canada) and 1X Penicillin, Streptomycin and Glutamine (Gibco,
ON, Canada). Cells were incubated at 37°C, in 85% O2 and 5% CO2. Cells were maintained at
0.2x106cells/mL, with re-seeding every 2 days.

2.1.2

In Vitro Differentiated Primary Th2 cells

Blood was obtained from a non-asthmatic healthy female donor [118] and was approved by
the Ethics Review Board at the University of Alberta (approval number 00000942). Using
density centrifugation over Ficoll Histopaque PLUS (GE Healthcare, Sweden), peripheral
blood mononuclear cells (PBMCs) were isolated. PBMCs underwent cell depletion to obtain
untouched CD4+ T cells using a CD4+ T cell Isolation Kit II (Miltenyi Biotech, CA, USA). This
protocol involved depletion of all non-CD4+ T cells through labeling with a cocktail of biotinconjugated antibodies and biotin antibody microbeads. These cells are magnetically labeled
and then depleted using a MACs column. Following cell depletion, CD4+ T cells T cells were
activated on plate bound CD3 antibody (Clone UCHT1, 1 g/mL) and CD28 antibody (Clone
37407, 1 g/mL) in Th2 polarizing conditions which included recombinant human (rh) IL-2
(5ng/mL) (R&D Systems, MN, USA), rhIL-4 (10-20ng/mL) (R&D Systems, MN, USA) and
antibodies against IFN-γ (polyclonal, 1µg/mL) and IL-12 (Clone C8.6, 1µg/mL) for 3 days.
Cells were then differentiated with blocking antibodies and cytokines after activation for 4
days. Anti-CRTh2 antibody coated microbeads (Miltenyi Biotech, CA, USA) were used to
obtain a population of CRTh2+ enriched cells. Cells from this line were frozen and re-cultured
in cell X-Vivo 15 media (Lonza, MD, USA) supplemented with 10 % FBS (Wisent, QC,
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Canada), 1X Penicillin, Streptomycin and Glutamine (Gibco, ON, Canada) and 5-10 ng/mL
IL-2 (MN, USA). Th2 cells were grown on cycles of plate bound anti-CD3 and anti-CD28 for
3 days/IL-2 only for 4 days with re-seeding at 2x106cells/mL.

2.2
2.2.1

CRTh2 Protein Abundance
Cell Lines and In Vitro Differentiated Th2 cell Experiments

CCRF CEM (0.2x106cells/mL) and primary Th2 cells (1.3x106cells/mL) were treated with
0.01-1μM Dexamethasone (DEX) (Sigma Aldrich, ON, Canada) and 0.01-10μM
Propylpyrazole-triol (PPT, Tochris, ON, Canada), which were both reconstituted in ethanol.
Cells were harvested with phosphate buffered saline (PBS) and washed in PBS FACS (0.5%
bovine serum albumin, 0.1% sodium azide, 3% FBS) prior to flow cytometry or standard PBS
prior to collection of supernatants and cell pellets for RNA isolation.

2.2.2

CRTh2 Surface Levels

To assess the effect of GC and ER signaling on CRTh2 surface levels, I used DEX, a highly
potent and classical GR agonist, and PPT, a well-known ER selective agonist. The effect of
this treatment on CRTh2 surface levels was assessed using CCRF CEM and primary Th2 cells.
Staining procedures were similar for both cell lines. Cells were washed in PBS FACS and
centrifuged (900 rpm, 10 minutes at 4◦C) and then re-suspended in fresh PBS FACS
(0.5x106cells/mL), incubated with Rat IgG blocking antibody (3mg/mL; Cederlane ON,
Canada) for 45 minutes at room temperature. Following blocking, cells were stained for
CRTh2 using anti-CRTh2 AlexaFluor 647 antibody (75ng/mL; BM16-rat IgG2a, Cederlane
ON, Canada) or isotype rat IgG2a Alexa647 control (Cederlane ON, Canada) on ice or in the
fridge (30 minutes). Cells were then washed in PBS FACS and fixed with 2%
paraformaldehyde. Flow cytometry analysis was performed using BD LSR II Flow Cytometer
at the London Regional Flow Cytometer Facility. Data was analyzed using FlowJo software
(Version 10, Ashland, OR, USA). Results are depicted as % of cells staining positive for
CRTh2 and mean fold intensity (MFI) which indicates the fluorescent intensity of CRTh2
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staining on each cell (MFI= [Mean Fluorescence Intensity Antibody – Mean Fluorescence
Intensity Isotype]/Mean Fluorescence Intensity Isotype).

2.2.3 Western Blot Analysis
Whole cell Lysate Preparation
Primary Th2 cells (1.3x106cells/mL) were treated with PPT and DEX for 24 hours and then
washed in PBS. Cell pellets were lysed at 4.0 x106 cells per 100 μL lysis buffer containing
RIPA buffer (1.0% TritonX-100, 0.5% deoxychloric acid, and 1X phosphate buffer) with 100
mM ETDA (pH 8.0), 10 g/mL of protease inhibitors Aprotinin and Leupeptin (SigmaAldrich, ON, Canada), 16 mg Sigma Fast protease inhibitor tablet and 100 mM
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, ON, Canada) added prior to use.
Protein lysates were incubated in lysis buffer for 30 minutes on ice and then centrifuged at
13000 rpm for 5 minutes at 4◦C. Supernatant was then collected and kept at -80◦C until protein
quantification.

Quantification of Whole Cell Lysates
Total protein concentration of supernatant was measured using the bicinchoninic acid reagent
(Pierce BCA Protein Assay Kit; Thermofisher Scientific, IL, USA) using bovine serum
albumin (BSA) as a standard according to the manufacturer’s manual. Protein sample was
added to the solution. The intensity of color change produced by the reaction is proportional
to the quantity of protein which is identified in comparison with its absorbance values to a
standard curve. The standard curve contained known concentrations of the standard protein
(diluted BSA) in the working range of 20-2000 µg/mL. Protein samples and standard protein
concentrations were quantified in a 96 well plate using a plate reader. The standard curve was
then plotted with its absorbance values (x-axis) and protein concentrations (y-axis) in Excel.
Sample absorbance value was determined by solving for x (sample absorbance) in y=ax+b and
the concentration of the sample determined. Total protein loaded for gel electrophoresis was
50 g.
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Gel Electrophoresis
Whole cell lysate samples were mixed with 2X sodium dodecyl sulfate (SDS) sample buffer
made with 100 mM Tris HCl (pH 6.8), 5% β-mercaptoethanol, 10% SDS, 20% glycerol, 0.1%
bromophenol blue and 5 mL distilled water. Samples were loaded on a 4% stacking and 10%
polyacrylamide gel and separated by electrophoresis. One lane contained the Precision Plus
Protein ladder (Bio-Rad, CA, USA) to estimate the molecular weight of bands. The gel was
run at 60 V for 30 minutes followed by 100 V for 1 hour. Following electrophoresis, gels were
kept in Tris-glycine transfer buffer (192 mM Glycine, 25 mM Trisma base, 20% methanol and
500 mL distilled water) for 15 minutes and wet-transferred onto a nitrocellulose membrane
(Bio-Rad, CA, USA) in Tris-glycine transfer buffer at 100 V for 1 hour on ice. Following this,
the transfer membranes were washed in Tris Buffer Saline with Tween 20 (TBS-T; 10 mM
Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween) and then blocked with 5% weight/volume
Carnation skim milk powder diluted in TBS-T for 4 hours at room temperature. Membranes
were then incubated with antibody against CRTh2 (rat monoclonal IgG2a; BM16, Santa Cruz,
TX, USA) diluted in 5% weight/volume Carnation skim milk (1:300) at 4°C overnight.
Membranes were then washed using TBS-T and were incubated with Goat anti-Rat IgG
Horseradish Peroxidase (HRP) secondary antibody (1:5000) diluted in TBS-T for 1.5 hours at
room temperature (JacksonImmunoResearch, PA, USA). The membrane was then washed
using TBS-T and re-incubated in fresh primary antibody overnight, washed and re-incubated
with secondary antibody. The presence of the secondary antibody conjugated to HRP was
detected using Clarity Western ECL substrate (Bio-Rad, CA, USA).

Imaging and GAPDH Quantification
A ChemiDoc MP Imaging System was used to acquire images of western blot membranes.
Exposure time for CRTh2 detection was optimized to 6 minutes. Following imaging,
membranes were stripped using a stripping buffer (192 mM glycine, 0.1% SDS, 1% Tween20;
pH 2.2 and ultrapure water). To strip the membrane for re-probing, the membrane was
incubated in stripping buffer for 10 minutes followed by washes in PBS and then washes in
TBS-T. The stripped membrane was then blocked for 1.5 hours in 5% skim milk before the
addition of GAPDH primary antibody. GAPDH antibody (Santa Cruz, TX, USA) was diluted
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in TBS-T. The membrane was incubated for 1.5 hours at room temperature (1:20000). GAPDH
protein bands were used as a loading control for densitometry analysis. Densitometry of protein
bands were performed using ImageJ program and CRTh2 total protein abundance was
normalized to GAPDH loading controls.

2.3

Th2 cell Response to CRTh2 Activation

Primary Th2 cells (1.3x106cells/mL) were pre-treated with DEX and/or PPT for 24 hours to
induce CRTh2, then washed and re-plated to assess the effect on CRTh2 activation. To do this,
cells were re-suspended in fresh media (RPMI or X-VIVO 15) in the presence or absence of
PGD2 (1.0 µM; Cayman Chemical, MI, USA) for 4 or 24 hours (Fig. 5). Cells were then
harvested, washed in PBS and cell pellets and supernatants collected for assessment of mRNA
and protein.

Figure 5: Th2 cell Response to PGD2 Activation
Since co-treatment with DEX/PPT enhances CRTh2 levels, cells were pre-treated for 24 hours
and then stimulated with PGD2 to assess if CRTh2 activity was increased, leading to more type
2 cytokine production.
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2.3.1

RNA Isolation and cDNA Synthesis

RNA was isolated using RNeasy Plus Mini Extraction kit (Qiagen, ON, Canada). RNA was
isolated from frozen cell pellets (2-6x106cells). RNA concentrations and purity was assessed
using NanoDrop 2000 (Thermo Scientific, Wilmington, Detroit) and a 260/280 and 260/230
ratio higher than 1.8 was used for cDNA. Complimentary DNA (cDNA) was synthesized using
400 ng of RNA, 4 µL iScript Reverse Transciption Supermix (Bio-Rad, CA, USA),
RNAse/DNAse free water (Lonza, MD, USA). Complimentary DNA (cDNA) synthesis was
conducted at 25°C for 5 minutes preceding 42°C for 30 minutes and 85°C for 5 minutes. cDNA
was diluted in 80μL of RNase/DNase free water stored at -20°C until qRT-PCR experiments
were conducted.

2.3.2

Quantitative Real Time PCR

Quantitative real time PCR (qRT-PCR) using TaqMan probe and primer sets (Life
Technologies, ON, Canada) were performed to assess mRNA levels of IL-5 (Hs01548712_g1)
and IL-13 (Hs00174379_m1) and were normalized to GAPDH (Hs02786624_g1). Reactions
were conducted using 10 µL of TaqMan Fast Advanced Master Mix (Applied Biosystems,
Foster City, California), 2 µL of cDNA and 7 μL of RNase/DNase free water to reach a final
reaction volume of 20 µL. CFX Connect Real-Time PCR Detection System (Bio-Rad, CA,
USA) was used for cDNA amplification. Thermo-cycling included Uracil-N-glycosylase
activation for 2 minutes at 50◦C following activation of polymerase at 95◦C, denaturing for 3
seconds following 30 seconds of annealing and extending at 60◦C for 40 cycles. Data was
analyzed by comparing the cycle thresholds (Ct) of the gene of interest to the housekeeping
gene GAPDH. The Ct of the house keeping gene was subtracted from the Ct of the gene of
interest to determine the Ct. To compare each condition relative to its control, the  Ct of the
control was subtracted from each condition conducted to determine the Ct for each
condition. The fold difference is then determined by calculating the Ct as a negative
exponent to the base of 2.
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2.3.3

Enzyme-Linked Immunosorbent Assay

Cell culture supernatants collected following CRTh2 activation by PGD2 and were assessed
for protein concentrations of type 2 cytokines by ELISA. A 96-well plate was coated with
capture antibody, covered and incubated overnight at 4◦C. The next day, liquid from the plate
was aspirated and washed 3 times in washing solution containing 1xPBS and 0.05% Tween20.
The plate was then blocked with blocking buffer containing 1xPBS and 5% BSA. The plate
was covered and incubated at room temperature for 2 hours. Following 2 hours of incubation
the liquid from the plate was aspirated and washed with washing solution containing 1xPBS
and 0.05% Tween20.
Standard vials provided in the IL-13 ELISA kit (Diaclone, France) and IL-5 ELISA kit
(Invitrogen, Austria) were reconstituted with standard dilution buffer as suggested by the
manufacturer. Reconstitution of the vials attains a stock solution of 100 pg/mL of IL-13 and
500 pg/mL of IL-5. The standard was serially diluted in tubes and pipetted onto the assay plate
which enabled a range of IL-13 and IL-5 protein concentrations and was conducted in
duplicates. The concentration of cytokine within each experimental samples were also assessed
in duplicates, with dilution of 1:200 for DEX treatments and 1:500 for remaining conditions.

Detection of IL-5
Biotinylated anti-IL-5 detection antibody was diluted 1:250 in ELISA diluent concentrate
which was diluted 1:5 in deionized water. Reconstituted detection antibody was added to each
well and the plate was covered and incubated at room temperature for 2 hours. Following
incubation liquid from the plate was aspirated and washed in washing solution. Enzyme
activity was detected using the protein streptavidin-conjugated to horseradish peroxidase
(HRP) enzyme. Streptavidin-HRP solution was added to each well and incubated at room
temperature for 30 minutes. Following incubation, liquid from the plate was aspirated and
washed in washing solution. Following this, 1X TMB substrate was added to each well. This
followed incubation of the plate for 15 minutes at room temperature. Following this stop
reagent containing 1N of sulfuric acid was added to each well to yield a yellow color.
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Detection of IL-13
Biotinylated anti-IL-13 detection antibody was reconstituted in reconstitution buffer
containing 1XPBS and 0.09% azide. Reconstituted detection antibody was further diluted in
secondary antibody dilution buffer containing 1XPBS and 1% BSA and was added to each
well. The plate was covered and incubated at room temperature for 1 hour and 30 minutes.
Following incubation liquid from the plate was aspirated and washed in washing solution.
Streptavidin-HRP was diluted in 1xPBS, 1% BSA, and 0.1% Tween20. After dilution,
Streptavidin-HRP solution was added to each well and incubated at room temperature for 30
minutes. Following incubation, liquid from the plate was aspirated and washed in washing
solution. Following this, TMB substrate provided by manufacturers was added to each well.
This followed incubation of the plate for 10 minutes in the dark at room temperature. Following
incubation, stop reagent containing 1N of sulfuric acid was added to each well to yield a yellow
color.

ELISA Quantification
The absorbance of each well was quantified using a spectrophotometer plate reader where 450
nm was set to be read as the primary wavelength and 650 nm was set as the reference wave
length. Results from the spectrophotometer were analyzed first by calculating the average
absorbance values of each set of duplicates used for standards and samples. A linear standard
curve was plotted using the average absorbance of each respective standard read out on the yaxis following its corresponding IL-13 or IL-5 concentration on the x-axis. To quantify the
amount of IL-13 or IL-5 in each sample, optical density values were extrapolated against the
standard curve containing standardized IL-13 or IL-5 concentrations.

2.4

Th2 cell Apoptosis

CCRF CEM cells (0.2x106cells/mL) and Th2 cells (1.3x106cells/mL in 1.25ng/mL IL-2) were
treated with DEX (0.1µM-1µM) in the presence or absence of PPT (0.1µM-10µM) for 48
hours. Some experiments tested PPT pre-treatment for 30 minutes prior to addition of DEX.
Apoptotic and dying cells were assessed by Annexin V and 7-Aminoactinomycin D (7-AAD)
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staining. Annexin V is an intracellular protein that works by its ability to bind to
phosphatidylserine which are typically found on the inner plasma membrane of cells [119].
During apoptosis, phosphatidylserines flip to the outer leaflet of the cell [119] and can be
detected using Annexin V labelled fluorochromes. Cells with compromised plasma membranes
are marked by DNA-staining dyes such as 7-AAD [119]. Assessing the proportion of Annexin
V+/7-AAD- cells identifies those undergoing early apoptosis, not yet positive for 7-AAD. Cells
(0.5x106) were washed in 1 mL PBS FACS, centrifuged and then re-suspended in 100 µL of
Annexin V binding buffer (10mM HEPES, 140mM NaOH, 2.5mM CaCl2 and 15.2 mL of
distilled H2O). Cells were then stained with the addition of 1 µL of Alexa Fluor 647 Annexin
V (BioLegend) and 4 µL of 7-AAD Viability Staining Solution (BioLegend). After 15 minutes
of incubation, cells were diluted with 400 µL Annexin V binding buffer and apoptosis and cell
death was assessed immediately using BD LSR II Flow Cytometer and analyzed by FlowJo
(Treestar, Ashland).
Expression of anti- and pro-apoptotic genes was assessed by qRT-PCR as in section 2.3.2 using
Taqman probe and primers sets (Life Technologies, ON, Canada) for BCL-2
(Hs00608023_m1), BCL-xL (Hs00236329_m1), BAD (Hs00188930_m1) and BIM
(Hs00708019_s1).

2.5

Statistical Analysis

Results from all experiments are presented as a mean + standard error of the mean (SEM) .
Statistical significance between experimental conditions were determined using a one-way
repeated measures ANOVA with a Holm-Sidak test. P-values less than 0.05 were considered
significant. N-values represent biological replicates of one primary Th2 cell line or an
immortalized T cell line (CCRF CEM). Statistical significance was assessed using Sigma Plot
(Version 12.5, CA, USA).
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Chapter 3

3

Results

3.1

GC and ER Signaling Upregulates CRTh2 by CCRF CEM
cells

To study GC response of Th2 cells, the highly potent synthetic corticosteroid, DEX, was used
to study/activate the GR. I used concentrations previously shown to upregulate FKBP5 mRNA,
a gene known to be induced by GR signaling [117, 120]. To assess the influence of ER
signaling on GC responses, PPT, a selective agonist for ER was used. The influence of ER
and/or GR signaling on CRTh2 surface levels was first assessed using an immortalized T
lymphoblastoid cell line (CCRF CEM) known to expresses CRTh2 [117]. These cells were
treated with PPT in the presence or absence of DEX for 24 hours. The effects of PPT and DEX
on CRTh2 protein was assessed by flow cytometry. No changes were seen in CRTh2 surface
levels with PPT alone (0.01-1.0 M) or DEX alone (0.1 M). However upon co-treatment with
PPT (0.1 M or 1.0 M) and DEX (0.1 M), CRTh2 surface levels were significantly increased
both in terms of the percentage of fluorescently positive cells (Fig. 6A) and the intensity of
staining per cell (Fig. 6B).
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Figure 6: CRTh2 Surface Levels in Response to GC and ER Signaling - CCRF CEM
cells
Surface levels of CRTh2 in CCRF CEM cells were determined by flow cytometry in response
to DEX and PPT treatment for 24 hours. The data represent percentage of cells expressing
CRTh2 (A) and the fluorescence intensity of CRTh2 staining per cell, expressed as mean fold
fluorescence intensity (MFI) (B) (n=5). Statistical differences (p<0.05) were determined by
using one way repeated measures ANOVA. Asterisks (*) represent significance vs control.

3.2

GC and ER Signaling Upregulates CRTh2 by Primary Th2
cells

CRTh2 protein abundance was increased upon co-treatment with PPT and DEX in CCRF
CEM, an immortalized T cell line. To confirm these finding, I repeated these experiments using
in vitro differentiated Th2 cells. Surprisingly, I found no significant change in the percentage
of CRTh2+ cells (Fig. 7A) or intensity of CRTh2 staining (Fig. 7B) in response to 1.0 M PPT
and 0.1 M DEX, unlike CCRF CEM. To assess whether concentration of PPT may have been
a reason for these differing results, I assessed the effect of using PPT at 10 M and found that
this combination did show an increase in surface CRTh2, both in terms of percentage of
positive cells (Fig. 7C) and intensity of staining (Fig. 7D).
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Figure 7: CRTh2 Surface Level in Response to GC and ER Signaling - Primary Th2
cells
Surface levels of CRTh2 by primary Th2 cells were determined by flow cytometry in response
to DEX and PPT treatment for 24 hours. The data represent percentage of cells expressing
CRTh2 (A/C) and the fluorescence intensity of CRTh2 staining per cell, expressed as mean
fluorescence fold intensity (MFI) (B/D) (n=5). Statistical differences (p<0.05) were
determined by using one way repeated measures ANOVA. Asterisks (*) represent significance
vs control.
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3.3

GC and ER Signaling Upregulates Total CRTh2 Protein
Abundance

Research indicates that CRTh2 can internalize in response to activation of various cell
signaling molecules such as arrestin-3 [121]. Since flow cytometry only assesses surface levels
of CRTh2, a western blot analysis was also performed to determine whether there was a change
in total protein. Figure 8 shows that co-treatment with PPT (10 M) and DEX (0.01 - 0.1 M)
significantly increased CRTh2 abundance (Fig. 8A&B).

Figure 8: Total CRTh2 Protein Abundance in Response to GC and ER signaling
Total CRTh2 protein abundance was determined by Western Blot analysis. Amount of CRTh2
in cells were determined in response to DEX and PPT treatment in primary Th2 cells for 24
hours. The data represents a Western Blot gel image for CRTh2 with GAPDH loading control
(A) and the total amount of CRTh2 protein quantified by densitometry (B) (n=3). Statistical
difference (p<0.05) was determined by using one way repeated measures ANOVA. Asterisks
(*) represent significance vs control.

35

3.4

GC and ER Signaling Enhances the Pro-inflammatory
Capacity of Th2 cells

3.4.1

GC and ER Signaling Enhances IL-5 Production

Since the activation of CRTh2 by its ligand PGD2 is known to mediate production of type 2
cytokines [28], I examined whether co-treatment with DEX/PPT increased Th2 cell response
to PGD2 by assessing IL-5 production. To assess this, primary in vitro differentiated Th2 cells
were pre-treated with DEX/PPT for 24 hours, then washed and stimulated with PGD2 to
activate CRTh2 for 4 hours or 24 hours. I found that the DEX/PPT enhancement of CRTh2
protein (Fig. 8) was not associated with higher levels of IL-5 mRNA (Fig. 9A and B) in
response to CRTh2 activation with PGD2 for 4 hours or 24 hours. In terms of protein, Th2 cells
showed a significant increase in IL-5 following stimulation with PGD2, which was inhibited
by pre-treatment with DEX. Th2 cells pre-treated with both DEX and PPT had higher levels
of IL-5 than DEX alone, but also more than Th2 cells that received no DEX at all (Fig. 10).
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Figure 9: Influence of GC/ER Pre-treatment on PGD2 Induction of IL-5 mRNA
Primary Th2 cells were pre-treated with DEX and/or PPT for 24 hours. Total IL-5 mRNA
levels were determined by qRT-PCR after stimulation with PGD2 for (A) 4 hours (n=3) and
(B) 24 hours (n=6) to activate CRTh2. Statistical difference (p<0.05) was assessed by one way
repeated measures ANOVA.
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Figure 10: Influence of GC/ER Pre-treatment on PGD2 Induction of IL-5 Protein
Primary Th2 cells were pre-treated with DEX and/or PPT for 24 hours. Total IL-5 protein
concentrations were determined by ELISA after stimulation with 24 hours PGD2 to activate
CRTh2 (n=6). Statistical difference (p<0.05) was determined by using one way repeated
measures ANOVA. Asterisks (*) represents significance vs DEX alone; number symbol (#)
represents significance vs control.
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3.4.2

ER Signaling Reverses GC Mediated Suppression of IL-13
Production

To assess whether the increase in CRTh2 following DEX/PPT treatment influences Th2 cell
capacity to produce other type 2 cytokines, I also assessed IL-13 production. In Th2 cells pretreated with DEX/PPT for 24 hours and then stimulated with PGD2, there was no significant
difference in IL-13 mRNA in response to 4 hours of PGD2 stimulation (Fig. 11A), though after
24 hours there did appear to be higher IL-13 mRNA in cells pre-treated with DEX/PPT
compared to DEX alone (Fig. 11B). Supernatant concentrations of IL-13 were higher in Th2
cells stimulated with PGD2, while pre-treatment with DEX inhibited this response.
Interestingly, Th2 cells pre-treated with both DEX and PPT produced IL-13 at concentrations
similar to PGD2 alone, indicating PPT reversed the DEX mediated suppression of IL-13 (Fig.
12).
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Figure 11: Influence of GC/ER Pre-treatment on PGD2 Induction of IL-13 mRNA
Primary Th2 cells were pre-treated with DEX and/or PPT for 24 hours. Total IL-13 mRNA
abundance were determined by qRT-PCR after stimulation with PGD2 for (A) 4 hours (n=6)
and (B) 24 hours (n=6) to activate CRTh2. Statistical difference (p<0.05) was determined by
using one way repeated measures ANOVA. Asterisks (*) represents significance vs DEX
alone.
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Figure 12: Influence of GC/ER Pre-treatment on PGD2 Induction of IL-13 Protein
Primary Th2 cells were pre-treated with DEX and/or PPT for 24 hours. Total IL-13 protein
concentrations were determined by ELISA after stimulation with PGD2 to activate CRTh2
(n=4). Statistical difference (p<0.05) was determined by using one way repeated measures
ANOVA. Asterisks (*) represents significance vs control or DEX alone.
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3.5

Effect of ER and GC Signaling on Th2 cell Apoptosis

Studies suggest that hormones affect T helper cell survival through their impact on specific
anti- and pro-apoptotic molecules, namely through the BCL-2 family [106]. Estrogen signaling
has been shown to increase BCL-2 expression in Th2 cells treated with E2 potentially allowing
for the selective survival of particular T cell subtypes [106]. This suggests that Th2 cells may
preferentially survive in environment with increased estrogen signaling resulting in a
dominance of humoral immune responses. Therefore, I studied whether GC induced apoptosis
can be inhibited by ER signaling.
To assess the influence of ER signaling on GC induced apoptosis, I first performed cotreatments with PPT (0.1 - 10 M) and DEX (1.0 M) of CCRF CEM cells for 48 hours. Figure
13A shows treatment with 1.0 M DEX significantly increased the proportion of Annexin V+
cells but that co-treatment with PPT had no effect. I then considered whether the PPT treatment
needed some time to take effect and so pre-treated CCRF CEM with PPT (30 mins) prior to
administering DEX. However, this also showed that PPT was not able to reduce DEX-induced
Annexin V+ cells (Fig. 13B). These results indicate using two experimental designs, that PPT
was not able to reduce apoptosis induced by 1.0 M DEX in CCRF CEM cells.
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Figure 13: ER Did Not Affect GC induced Apoptosis in CCRF CEM cells
CCRF CEM cells were treated with DEX and PPT for 48 hours to assess apoptosis with flow
cytometry. Percentage of Annexin V+ cells when PPT and DEX were added together (A) (n=4)
or when PPT was given 30 minutes prior to adding DEX (B) (n=3). Statistical difference
(p<0.05) was determined by using one way repeated measures ANOVA. Asterisks (*)
represents significance vs control.
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3.6

ER Signaling Reduced GC Induced Apoptosis in Primary Th2
cells

To further test whether ER signaling can influence GC induced apoptosis, I performed
experiments with primary Th2 cells and a titration of DEX. The proportion of 7-AAD-Annexin
V+ cells (Fig. 14) were increased similarly with all DEX concentrations. When assessing the
effect of PPT (1.0 M), I found no effect on the proportion of cells staining for 7-AAD (Fig.
15A), though PPT did reduce the proportion of Annexin V+ cells induced by the lower DEX
concentrations (0.1 M, 0.5 M; Fig. 15B). The Annexin V+/7-AAD- population (Fig. 15C, D)
showed similar results to total Annexin V+ staining (Fig. 15B), suggesting the effect was on
apoptosis, though this was not significant.

Figure 14: GC Induced Apoptosis in Primary Th2 cells
Primary Th2 cells were treated with DEX for 48 hours to assess apoptosis by flow cytometry.
Percentage of Annexin V+ 7-AAD- cells were assessed (n=3). Statistical difference (p<0.05)
was determined by using one way repeated measures ANOVA. Asterisks (*) represents
significance vs control.
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Figure 15: ER Effects on GC induced Apoptosis in Primary Th2 cells
Primary Th2 cells were treated with DEX and PPT for 48 hours to assess cell death apoptosis
by flow cytometry. (A) Percentage of 7AAD+ and (B) Annexin V+ cells following co-treatment
with PPT and DEX (n=3). (C) Effect of PPT on Annexin V+/7-AAD- cells treated with low
and (D) moderate DEX concentrations. Statistical difference (p<0.05) was determined by using
one way repeated measures ANOVA. Asterisks (*) represents significance vs DEX alone.
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3.7

Effect of ER and GC Signaling on Apoptotic Gene Expression
in Primary Th2 cells

Since my data suggested PPT influences DEX induced apoptosis, I next examined expression
of pro-/anti-apoptotic genes. Primary Th2 cells were treated with DEX (0.1 M, 0.5 M, and
1.0 M) and PPT (1.0 M) for 48 hours. The level of mRNA for BCL-2, BCL-xL, BIM and
BAD were assessed. I found that while PPT alone did not increase BCL-2 mRNA levels, they
were significantly higher when cells were co-treated with PPT (1.0 M) and DEX (0.1 M and
0.5 M) compared to DEX alone (Fig. 16A). When looking at BCL-xL, another anti-apoptotic
factor, mRNA levels showed no significant change (Fig. 16B). Previous studies have shown
that GCs can induce apoptosis by upregulating BIM, a pro-apoptotic factor [77]. When
assessing BIM mRNA levels, I found increased BIM levels in cells that were cultured in a high
concentration of DEX (1.0 M). Interestingly, I found that the level of BIM mRNA was
significantly reduced when Th2 cells were co-treated with PPT (1.0 M) and DEX (1.0 M)
(Fig. 16C), though not at lower DEX concentrations (0.1M and 0.5 M). Assessment of BAD,
another pro-apoptotic member of the BCL-2 family, showed no significant changes upon DEX
and PPT treatment (Fig. 16D).
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Figure 16: Apoptotic Gene Expression by Th2 cells Following ER and GC Treatment
Primary Th2 cells were treated with DEX and PPT for 48 hours. BCL-2, BCL-xL, BIM and
BAD mRNA transcript levels were determined by qRT-PCR (n=3). Statistical difference
(p<0.05) was determined by using one way repeated measures ANOVA. Asterisks (*)
represents significance vs DEX alone; number symbol (#) represents significance vs control;
ns represents not significant vs control.
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4

Discussion

A study of inhaled corticosteroids showed a more significant improvement in airway
responsiveness and lung function (FEV1) in men than women [89]. Our laboratory has
observed that severe asthmatic women had a higher proportion of circulating Th2 cells than
men (App. 1.1) and that Th2 cells were positively correlated with daily dose of inhaled GC in
women, but not men (App. 1.2). Since estrogen has been shown to induce expression of type
2 cytokines [93, 105], it may play a role in influencing Th2 cell responses to GC. I found that
Th2 cells co-treated with GC and an ER agonist exhibited significant increases in CRTh2
protein abundance and IL-5 production in response to PGD2 as well as resistance to GC induced
apoptosis. Overall these data suggest that in vivo estrogen signaling may interfere with the antiinflammatory effects of glucocorticoids, allowing for increased Th2 cell function and survival
which may mediate asthma severity in women.

4.1

Effect of GC and ER Signaling on Th2 cell Responses

I utilized an experimental setup of Th2 cells exposed to GC alone or in combination with an
ER agonist to model GC responses in men (DEX alone) and women (DEX + PPT). I found
no effect on CRTh2 levels when an ER agonist was added alone, though when Th2 cells were
treated with both GC and an ER agonist there was a significant increase in CRTh2. While the
level of GC present in the serum is not known, this did not appear to influence DEX effects as
preliminary work showed similar results even with 0% serum [117]. Our first experiments were
performed using flow cytometry and while I did observe increases in the CCRF CEM cell line,
I initially failed to see this increase in primary Th2 cells. This difference may have been due
to difference in receptor levels between cell lines. Indeed, our qRT-PCR results indicated the
mRNA level for ESR1, the gene encoding ER, was 1.6-fold higher in CCRF CEM cells
compared to primary cells (App. 1.3), though this was not statistically significant. On the other
hand, increasing the concentration of PPT in the co-treatment resulted in higher CRTh2 surface
levels, which may indicate that the lower concentrations of PPT were not sufficient to
maximally activate ER. A study assessing the selectivity of PPT for ER, using ER and
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ER expression vectors and promoter reporter constructs from estrogen responsive genes
containing EREs, found that PPT was highly selective for ER, with no stimulation of ER at
concentrations below 1M [122]. In my experiments with primary Th2 cells 10 M PPT was
required to see increases in CRTh2. Future work should be done to assess the selectivity of this
agonist at this higher concentration, as it cannot be ruled out that effects may have been through
ER or even GPER. Nonetheless, these data suggest that receptor level can affect the ability
of estrogen to influence GC responses. This may be relevant clinically, since my laboratory
has observed that ESR1 levels in whole blood RNA preparations are lower in severe asthmatic
men compared to women (App 1.4).
Our flow cytometry analysis of CRTh2 levels in both CCRF CEM cells and primary Th2 cells
indicated that the cells were not 100 percent positive for CRTh2. Our analysis showed basal
levels of cells expressing CRTh2 to range from 30-60 percent. Similar to other receptors, such
as GR and ER, it could be possible that CRTh2 is cell cycle regulated [123, 124]. Contrarily,
we also do not know whether the increases observed in CRTh2 levels were as a result of low
expressers or due to the whole cell population. Future work could examine this by sorting
CRTh2 positive cells from these lines and re-assessing the DEX/PPT effect on a highly CRTh2
enriched (>80%) cell population. G-protein coupled receptors like CRTh2 have also been
shown to display immediate desensitization and internalization upon activation by cell
signaling molecules [121]. Upon internalization, CRTh2 can either be subject to degradation
or recycling back to the cell surface [121]. Therefore, it is also possible that the increase in
surface CRTh2 I observed was due to repositioning rather than upregulation of CRTh2 surface
levels. Since basal levels of CRTh2 differed between the experiments testing 1M PPT
compared to 10 M PPT, I decided to assess the influence of DEX/PPT on CRTh2 abundance
using a western blot analysis. This analysis clearly showed that total CRTh2 abundance was
upregulated by co-treatment with PPT/GC, suggesting ER signaling may maintain the Th2
cell population in the presence of GC treatment. Moreover, although GC action is considered
to be anti-inflammatory, I did not observe GC reducing CRTh2 levels. In some experiments
CRTh2 surface levels looked increased, though this was not statistically significant. This is
similar to other surface receptors such as receptors for IL-2 and TSLP which have been shown
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to be increased by GC and part of a new concept that not all aspects of GC treatment are antiinflammatory [125, 126]. The ligand for CRTh2 is PGD2, released from mast cells following
allergen activation [37]. CRTh2 activation mediates chemotaxis of Th2 cells and ILC2 [127]
and so overall these data could suggest that increased levels of CRTh2 in the context of dual
GC/ER signaling may result in more CRTh2-expressing cells infiltrating the airways of
asthmatic women.
I found that PGD2 induced IL-13 protein concentrations, similar to previous reports [116, 128],
and that pre-treatment with GC was able to inhibit this effect. However, I did not observe that
PGD2 induced IL-5 protein concentrations. Though the effects of PGD2 on IL-5 cytokine
induction may not have been observed due to pre-existing high basal levels of IL-5, these
results suggests that there may be potential differences in IL-5 and IL-13 regulation. In
addition, I also observed a failure of GC to inhibit both IL-5 and IL-13 in the presence of the
ER agonist, suggesting that in women estrogen signaling could dampen the antiinflammatory capacity of GC treatment. The inability to see mRNA modulation of IL-5 or IL13 may have been due to time sensitive cellular effects requiring a longer exposure to PGD2.
Indeed, Xue et al observed that IL-5 and IL-13 mRNA regulation differed over varying time
points upon activation by PGD2 [128]. Collectively, these results show the ability of ER to
reverse the suppressive effects of GC on type 2 cytokine production. Since IL-5 and IL-13
promote many aspects of inflammation such as tissue eosinophilia, mucous production and
airway hyper-responsiveness [129], their persistent expression may play a role in asthma
severity in women. This would also be in line with findings that peri-menstrual asthma patients
have been shown to have increased sputum IL-5 concentrations [93].

GCs are known to mediate their effects through the direct binding of GC to the GR. This
complex binds GRE within the promoter of target genes or through its interaction with other
transcription factors (eg. AP-1 or NFB) and this ultimately leads to the repression of proinflammatory genes expression [57, 59]. When looking at the chromosomal arrangement, the
genes encoding for IL-5 and IL-13 are situated in close vicinity on the 5q chromosome in
humans [130]. Transcription of IL-5 and IL-13 is also regulated through binding of nuclear
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factor of activated T cells activator protein 1 (NF-AT-AP-1) and GATA-3 [131, 132]. GCs
have been shown to interfere with expression of these cytokines by the binding of GC-GR
complex to NF-AT-AP-1 sites [131]. GR can also inhibit NF-AT-AP-1 protein levels [133],
which would influence level of recruitment to the promoter of IL-5 or IL-13. Lastly, treating
cells with trichostatin A (TSA), a modulator of histone activation, has been shown to influence
the ability of GR to suppress IL-5 and IL-13 expression [131], indicating that another role may
be through recruitment of repressor complexes [131].

Various aspects of GR function are likely perturbed in the presence of ER signaling. For
instance, a competition model would suggest the PPT-ER complex may bind to the same
element that the DEX-GR complex binds to on the IL-5 or IL-13 promoter, thereby limiting
the binding of GR. Another possibility is that potentially GR and ER complexes may form
and bind at different regions on the promoter of IL-5 or IL-13, leading to altered recruitment
of various transcription factors or co-factors that may be important for DEX induced
repression. Although, the mechanisms regarding the cross-talk between estrogen and GC are
not well known, studies done on breast cancer cell lines have shown that estrogen does not
affect GR nuclear translocation but works to reduce phosphorylation that occurs upon ligand
binding at Ser-211, a residue important for GRs active form. Furthermore, protein
phosphatases (PP) have been shown to regulate GR phosphorylation, PP5 in particular has
been shown to be associated in estrogen mediated GR inhibition, therefore it is possible that
ER signaling could affect GR phosphorylation resulting in an upregulation of type 2 cytokines
like IL-5 and IL-13 [115].

Surprisingly, the influence of ER signaling on GC mediated repression differed for IL-5 and
IL-13. In the case of IL-13, GC suppression of PGD2 mediated expression was reversed by
ER agonist. For IL-5, the concentrations were actually higher with ER agonist and GC,
compared to GC alone as well as treatment with no GC. As noted above, IL-5 and IL-13
transcription is mediated by a similar set of transcription factors such as NFAT, AP-1 and
GATA3 [134, 135]. Therefore, it is unclear whether the differential effect of ER signaling is
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from the level of transcription, though it is possible that these factors exhibit subtly different
methods of promoter activation. On the other hand, it is possible these cytokines were similarly
influenced by ER agonist but that the analysis at 24 hours did not capture these differences,
as they have been shown to exhibit different expression kinetics [128]. This could be
determined by performing a more granular time point analysis. Additionally, if the influence
of dual GR/ER signaling is truly greater on IL-5 than IL-13, this could lead to asthmatic
women having more pathogenic Th2 (pTh2) cells, a recently described subset of Th2 cells.
This subset is characterized by high intensity IL-5 staining and are positively correlated with
eosinophilia [136].

4.2

GC and ER Signaling on Th2 cell Survival

Previous studies have shown that estrogen signaling serves as an inhibitor of apoptosis in
diseases like breast cancer [137] and in animal model studies [138]. My results showing that
ER signaling reduced the proportion of Annexin V+ cells, but not 7-AAD+ cells, suggests that
ER signaling can reduce apoptosis induced by GC. Analysis of Annexin V+/7-AAD- cells,
identifying early apoptotic cells that still have intact plasma membrane, supports this
conclusion though more experiments are needed to strengthen this result. Alternatively another
approach to confirm my apoptosis findings could be to assess Caspase activation. Moreover,
the ability of ER signaling to inhibit GC induced apoptosis was only seen at low/moderate
concentrations of GC and there was no effect when ER was activated prior to GC addition.
These observations suggest the effect of ER signaling on GC is due to its direct interaction
with GR and that the stoichiometry of these receptors may be important. Together, these data
suggest that ER signaling interferes with the ability of GC to induce apoptosis. In vivo, this
could represent a mechanism by which Th2 cells are sustained in women, but not men, with
severe asthma.
Alterations in BCL-2 expression have been previously associated with resistance to
chemotherapy allowing for the persistence of cancer cells [139]. In GC induced apoptosis the
balance between pro-and anti-apoptotic members is essential in permitting the apoptosis of
targeted cells [139]. There are approximately 25 members of the BCL-2 family consisting of
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pro- and anti- apoptotic molecules. In certain diseases, BCL-2 is commonly found to be more
highly expressed resulting in a lack of apoptosis and cell death thereby contributing to disease
persistence [140]. Furthermore, over-expression of members such as BCL-2 and BCL-xL in
cell lines have been shown to result in T cells that are resistant to GC induced apoptosis [141,
142]. While I did not observed much increase in BCL-2 in response to ER agonist alone, Th2
cells co-treated with both ER and GC agonists showed a significant induction of BCL-2
mRNA compared to control (6-fold) as well as GC alone (4-fold). These findings are supported
by those of others showing that E2 increased the expression of BCL-2 in Th2 cells [106].
Interestingly, the highest levels of BCL-2 mRNA were observed when ER agonist was added
to the lowest concentrations of DEX (0.1 M and 0.5 M). Taking the Annexin V+ staining
and mRNA data together, I conclude the effect of ER agonist was on GC induced apoptosis.
BIM mRNA, on the other hand, was significantly induced by Th2 cells when cultured in a high
DEX (1.0 M) concentration. The ER agonist only reduced BIM levels at the higher
concentration of DEX (1.0 M), a concentration where ER agonism was unable to modulate
the proportion of Annexin V+ cells. Collectively, these results show that the ER effect on GC
induced apoptosis appears to be through driving expression of BCL-2, rather than reducing
levels of BIM. As such, targeting BCL-2 protein [143] may be beneficial in alleviating GC
resistance to permit Th2 cell apoptosis in severe asthmatic women.

4.3

Future Work and Limitations

These data show that signaling between GR and ER upregulates CRTh2 levels, though the
mechanism underlying this upregulation is not well understood. It would be interesting to study
whether both receptors interact in either a direct or indirect fashion. Protein-protein interactions
can be studied between GR and ER using the split ubiquitin system. This assay fuses GR and
ER into two different DNA binding domains. Direct protein interactions can be identified
when there is expression of the reporter gene upon binding of both proteins to the regulatory
region of the gene. Examination of ER and GR interactions can be followed by experiments
to determine the mechanisms by which both receptors upregulate CRTh2. This could be studied
53

by transfecting Th2 cells with a CRTh2 luciferase reporter construct and assessing how ER
and GR expression vectors effect the CRTh2 promoter activation.
Studies have shown that members of the -arrestin family can play a role in CRTh2 trafficking
and signaling [121]. Indeed, a study has shown that -arrestin can bind the c-terminal tail of
CRTh2 allowing the receptor to undergo rapid desensitization thereby inhibiting its function
[144]. Since our preliminary RNA sequencing analysis (n=1) shows a downregulation of arrestin in Th2 cells treated with DEX/PPT (L. Solomon, unpublished), this could be
mechanism by which ER and GC signaling may enhance CRTh2 surface levels and/or
increase its function. Future work could focus on studying the differential regulation of
members of the -arrestin family and their role on CRTh2 signaling. This may elucidate a
mechanism underlying the DEX/PPT enhancement of CRTh2 and Th2 cell function. This
could be done through qRT-PCR analysis to assess -arrestin mRNA levels as well as a
western blot analysis to identify protein differences in -arrestin. To assess impacts CRTh2
signaling and function an RNA knock out of the -arrestin gene in Th2 cells could determine
if there is enhanced signaling and cytokine production with DEX/PPT treatment.
The effects on IL-5 and IL-13 also warrant more investigation such as assessing expression of
genes and transcription factors involved in the upregulation of these cytokines upon ER and
GC treatment. A genome wide expression analysis can by conducted by RNA sequencing to
accomplish this. Upon identification of potential gene targets involved, binding of ER-GR
can be determined using chromatin immunoprecipitation (ChIP). A ChIP analysis can also help
identify whether GR and ER bind the IL-5 or IL-13 promoter or influence the binding of
other transcription factors. The mechanism by which GR and ER regulate IL-5 and IL-13 can
further be studied by transfecting primary Th2 cells with IL-5 or IL-13 promoter constructs to
determine if GR and ER expression vectors differentially regulate promoter activation of
these cytokines.

The examination of the mechanisms underlying the ability of ER to influence apoptosis are
interesting, however, the changes in BCL-2 and BIM mRNA levels need to be confirmed at
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the level of protein. This may have been a factor in my failure to see differences in expression
of other members of the BCL-2 family such as BAD and BCL-xL. Determining total protein
abundance using techniques like western blot would help us better understand whether total
protein changes correlate with mRNA differences. This can help us further understand which
members in the BCL-2 family are playing a role in the ER mediated reduction of GC induced
apoptosis. However, other data generated by our laboratory using RNA sequencing and
pathway analysis does substantiate these findings as it also shows upregulation of BCL-2 and
other members of the anti-apoptotic pathway in Th2 cells treated with DEX/PPT (L. Solomon,
unpublished). In addition, although Annexin V+ staining is a reliable indicator of early
apoptosis, experiments assessing Caspase activity should be performed to confirm that PPT
did indeed reduce DEX-induced apoptosis.

ER activity may largely depend on the level of receptor available within the cell. My results
show that dose of PPT was influential in increasing CRTh2 surface levels. Measurement of
protein levels of ER between cell lines would help us identify whether availability/level of
receptor influences Th2 cell responses and CRTh2 induction. Preliminary data generated for
this thesis was obtained using CCRF CEM cells, an immortalized cell line. It is likely these
cells have undergone genetic and phenotypic changes suggesting cells within the line may be
different from those cells from which they originated. This brings us to question whether CCRF
CEM cells would perfectly model typical Th2 cells. To address this limitation we validated
experiments using primary Th2 cells derived from a female non-asthmatic healthy donor. Since
the data obtained were from one female donor, it is not known whether this is reflective of the
level found in all ‘female’ Th2 cells, inter-individual variability and/or due to long-term
culture. Therefore, experiments should be conducted to validate these findings in more female
primary Th2 lines. Moreover, although I have shown that treating Th2 cells from a female
donor with DEX and an ER agonist significantly increased CRTh2 levels, it is unclear
whether Th2 cells from men and women differentially regulate CRTh2 levels and Th2 cell
responses. Therefore, we must examine Th2 cell responses in cells isolated from men and
women to identify intrinsic vs extrinsic differences in Th2 cells. Our findings show a positive
correlation between Th2 cells and inhaled corticosteroids in women with severe asthma but
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not men, suggesting Th2 cells from men and women with severe asthma respond differentially
to GCs. Therefore, we should also assess GC responses in Th2 cells obtained from men and
women with severe asthma.

Studies have indicated that estrogen signaling can upregulate the cytokine TSLP as well
proteins such as CD86 and FOSL1 [145-147]. Interestingly, preliminary data generated by our
laboratory using RNA sequencing (n=1) shows that transcript levels for TSLP, FOSL1 and
CD86 are increased with PPT treatment (L. Solomon, unpublished). These findings suggest
that PPT is promoting estrogen signaling, though further validation of these mRNA results are
needed. Another limitation is that this study examined the role of ER signaling on Th2 cell
responses, while in vivo Th2 cells are exposed to estrogens which could also act on ER and
even GPER. Therefore future experiments should be conducted using at least E2, one of the
major forms estrogen to assess the overall effect of estrogen signaling. Additionally using ER,
ER, and GPER agonists/antagonists will improve our understanding of the distinct role that
each receptor has on Th2 cell responses to GC.
Estrogen signaling in this study has been shown to interfere with the anti-inflammatory effects
of GCs. Although this is one possibility for reduced GC efficacy in patients it is possible that
other factors may also influence efficacy of GCs. For instance in some cases patients
experience resistance to the anti-inflammatory effects of GC treatments and studies have
shown that this may be related to alterations in GR and GR expression [148].
Proinflammatory cytokines have been shown to enhance AP-1 transcription resulting in
impaired GR activation thereby influencing GC sensitivity [148]. Studies have also shown
that increased GR levels are associated in diseases like ulcerative colitis, nasal polyposis, and
asthma [56]. Indeed, increased GR expression has been shown to be associated with a
reduction in GC mediated apoptosis allowing for the persistence of cells that mediate
inflammation [149]. Therefore assessing GR/GR receptor levels may be beneficial in future
experiments. Furthermore, as GCs enter circulation they are eventually metabolized within the
lung and liver by enzymes of the cytochrome p450 (CYP3A) family [150]. A study has also
found that differences in the expression of members of the CYP3A family can influence the
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pharmokinetics of GCs action, which could ultimately affect its anti-inflammatory effects
[151]. It is possible that variability in GC metabolism between men and women could be
related to expression of CYP3A members and that this may mediate steroid insensitivity.
Indeed, a study has shown that women express higher levels of CYP3A4, which could
potentially influence sex differences in GC metabolism [152]. Therefore, studying the role of
CYP3A may also provide more context on mechanisms of steroid insensitivity.
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4.4

Conclusion

This study examined the interaction between estrogen and glucocorticoid receptor signaling in
Th2 cells and showed that activating ER may interfere with the anti-inflammatory effects of
GCs. Indeed, estrogen-mediated increases in the pro-inflammatory potential of Th2 cells along
with its ability to reduce GC mediated apoptosis may be a mechanism influencing the
development of severe asthma in women. These data suggest that the effects GC may differ
between men and women and that this should be tested. Furthermore, new therapies that target
Th2 cells such as an antagonist against CRTh2 should be assessed in both men and women to
determine whether there are sex-specific responses.

Figure 17: Potential Mechanism of Action. Estrogen and GC diffuse through the plasma
membrane and bind to their respective receptors (ER or GR). Both receptors translocate to
the nucleus and upregulate CRTh2 transcription, either directly or indirectly (unknown),
thereby increasing CRTh2 surface and total protein abundance. Enhanced CRTh2 levels make
Th2 cells more responsive to PGD2, resulting in more IL-5 and IL-13 production (Aim 1). ER
also reduced GC-induced apoptosis and induced BCL-2 mRNA (Aim 2), potentially mediating
increased survival of Th2 cells in women.
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Appendix 1
Data within this appendix section was developed by prior members of Dr. Lisa Cameron’s
laboratory. This data will go in combination with my data to generate a final publication.

Appendix 1.1: Circulating Th2 cells in Asthmatic Men and Women. Circulating Th2 cells
in asthmatics are women with severe asthma but not men. Data provided by Drs. Nami Shrestha
Palikhe and Lisa Cameron.
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Appendix 1.2: Circulating Th2 cells and Total Daily Dose of Inhaled Steroid. Circulating
Th2 cells in asthmatics are positively correlated total daily dose of inhaled corticosteroids in
women (A), but not men (B). Data provided by Drs. Nami Shrestha Palikhe and Lisa Cameron.
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Appendix 1.3: ESR1 mRNA Levels in CCRF CEM and Primary Th2 cells. Level of
mRNA for ESR1, the gene encoding ER, in CCRF CEM and Primary Th2 cells determined
by qRT-PCR. Data provided by Tharsan Kanagalingam and Dr. Lauren Solomon.

Appendix 1.4: ESR1 mRNA Levels in Asthmatic Men and Women. Level of mRNA for
ESR1, the gene encoding ER, in mild/moderate and severe asthmatics determined by qRTPCR. Data provided by Drs. Nami Shrestha Palikhe and Lisa Cameron.
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